Product Name
KCNA1, siRNA
Full Product Name
KCNA1 siRNA (Mouse)
Product Synonym Names
Potassium voltage-gated channel subfamily A member 1; MBK1; MKI; Voltage-gated potassium channel subunit Kv1.1
Product Gene Name
KCNA1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P16388
Specificity
KCNA1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse KCNA1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of KCNA1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
KCNA1 sirna
siRNA to inhibit KCNA1 expression using RNA interference
Applications Tested/Suitable for KCNA1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for KCNA1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_034725.3
[Other Products]
NCBI GenBank Nucleotide #
NM_010595.3
[Other Products]
UniProt Primary Accession #
P16388
[Other Products]
UniProt Related Accession #
P16388[Other Products]
Molecular Weight
56,409 Da
NCBI Official Full Name
potassium voltage-gated channel subfamily A member 1
NCBI Official Synonym Full Names
potassium voltage-gated channel, shaker-related subfamily, member 1
NCBI Official Symbol
Kcna1 [Similar Products]
NCBI Official Synonym Symbols
MBK1; Mk-1; Shak; Kv1.1; mceph; Kca1-1; AI840627
[Similar Products]
NCBI Protein Information
potassium voltage-gated channel subfamily A member 1
UniProt Protein Name
Potassium voltage-gated channel subfamily A member 1
UniProt Synonym Protein Names
MBK1
Protein Family
Potassium voltage-gated channel subfamily
UniProt Gene Name
Kcna1 [Similar Products]
UniProt Entry Name
KCNA1_MOUSE
UniProt Comments for KCNA1
Kv1.1: Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient. Defects in KCNA1 are the cause of episodic ataxia type 1 (EA1); also known as paroxysmal or episodic ataxia with myokymia (EAM) or paroxysmal ataxia with neuromyotonia. EA1 is an autosomal dominant disorder characterized by brief episodes of ataxia and dysarthria. Neurological examination during and between the attacks demonstrates spontaneous, repetitive discharges in the distal musculature (myokymia) that arise from peripheral nerve. Nystagmus is absent. Defects in KCNA1 are the cause of myokymia isolated type 1 (MK1). Myokymia is a condition characterized by spontaneous involuntary contraction of muscle fiber groups that can be observed as vermiform movement of the overlying skin. Electromyography typically shows continuous motor unit activity with spontaneous oligo- and multiplet-discharges of high intraburst frequency (myokymic discharges). Isolated spontaneous muscle twitches occur in many persons and have no grave significance. Belongs to the potassium channel family. A (Shaker) (TC 1.A.1.2) subfamily. Kv1.1/KCNA1 sub-subfamily.
Protein type: Channel, potassium; Membrane protein, multi-pass; Membrane protein, integral
Cellular Component: voltage-gated potassium channel complex; cell surface; integral to plasma membrane; endoplasmic reticulum; dendrite; paranode region of axon; integral to membrane; cytosol; presynaptic membrane; cell projection; membrane; cell soma; axon; apical plasma membrane; plasma membrane; synapse; cytoplasmic vesicle; nerve terminal; cell junction
Molecular Function: voltage-gated potassium channel activity; potassium channel activity; delayed rectifier potassium channel activity; ion channel activity; voltage-gated ion channel activity
Biological Process: startle response; regulation of muscle contraction; neuromuscular process; hippocampus development; generation of action potential; detection of mechanical stimulus involved in sensory perception of pain; regulation of membrane potential; transport; neuroblast proliferation; ion transport; brain development; transmembrane transport; protein homooligomerization; potassium ion transport; detection of mechanical stimulus involved in sensory perception of touch
Research Articles on KCNA1
1. The Kv1.1 null mouse is a potential model for sudden unexpected death in epilepsy in patients
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
